2022.07.22
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
I-Mab today announced that the first patient in China has been treated with TJ-CD4B in a Phase 1 IMCT for patients with solid tumors.